WINNIPEG, MANITOBA--(Marketwire - May 20, 2008) - Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, announces today that it will be conducting a 2nd pivotal pre-biopsy screen study for its urine based P2V™ prostate cancer diagnostic test.
